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INTRODUCTION
The incidence and mortality of epithelial ovarian cancer have 
continuously increased in Korea.1-3 Epithelial ovarian cancers 
are classified according to histologic subtypes into high-grade 
serous carcinoma (HGSC), clear cell carcinoma, endometri-
oid carcinoma, mucinous carcinoma, low-grade serous carci-
noma (LGSC), and carcinosarcoma. According to the Korean 
Cancer Registry, histologic subtypes other than HGSC (non-
HGSC) comprised more than half of the epithelial ovarian 
cancer cases in 2012. Furthermore, the incidence of clear cell 
carcinoma has significantly increased across all age groups in 
Korea.4
Although the prognosis and underlying carcinogenesis of 
epithelial ovarian cancer histologic subtypes are different, 
current treatment guidelines are the same for all. In previous 
studies, histologic subtype was identified as an independent 
prognostic factor. Among patients with advanced ovarian can-
cer, those with a non-HGSC subtype were deemed to have a 
relatively poor prognosis, compared with HGSC, due to resis-
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1) pulmonary and/or hepatic parenchymal metastases were 
observed on initial imaging studies, 2) patients had poor per-
formance status and high operative risk due to medical co-
morbidities, or 3) optimal debulking surgery (residual disease 
measuring 1 cm or less) was unsuitable due to high tumor 
burden (Fagotti score ≥8).19
All patients received taxane-platinum combination chemo-
therapy. Conventional surgical procedures consisted of total 
hysterectomy, bilateral salpingo-oophorectomy, omentecto-
my, and pelvic/para-aortic lymphadenectomy. Radical sur-
geries included bowel resection, diaphragm/peritoneal sur-
face stripping, splenectomy, liver resection, partial gastrectomy, 
partial cystectomy/ureteroneocystostomy, cholecystectomy, 
and/or distal pancreatectomy. All surgical procedures were 
performed by one of five gynecologic oncology surgeons at a 
single institute.
The following data were extracted from patient medical re-
cords: age, body mass index (BMI), cancer antigen (CA)-125 
levels, FIGO stage, tumor histology, American Society of An-
esthesiologists (ASA) score, performance of radical surgery, 
residual disease after IDS, and chemotherapy regimen. Ra-
diologic evaluation was performed after three cycles of NAC 
to evaluate the responses to treatment based on the Response 
Evaluation Criteria in Solid Tumors.20 After IDS, patients re-
ceived various cycles of postoperative adjuvant chemotherapy 
(POAC).
Overall survival (OS) was defined as the time from the date of 
first chemotherapy to the date of death. Progression-free sur-
vival (PFS) was defined as the time from the date of first che-
motherapy to the date of first recurrence. A gynecologic pa-
thologist (H.S.K.) at our institution independently reviewed 
all microscopic slides according to the World Health Organi-
zation classification for accuracy of histologic subtyping.
Statistical analysis
Patients were classified by histological subtype into HGSC 
tance and reduced sensitivity to standard chemotherapy.5-11 
Several studies have evaluated subtype-specific treatment of 
advanced ovarian cancer to improve the survival of patients 
with non-HGSC. However, these studies were performed only 
in patients who underwent primary debulking surgery (PDS).12-15
For advanced-stage ovarian cancer, neoadjuvant chemo-
therapy (NAC) and interval debulking surgery (IDS) have been 
proposed based on two randomized, controlled, phase III tri-
als demonstrating no inferiority of IDS compared with PDS 
for the treatment of advanced ovarian cancer.16,17 Responses 
to chemotherapy and clinical/surgical outcomes after the ad-
ministration of NAC have been widely studied, mainly focus-
ing on HGSC. As non-HGSC is now considered a different dis-
ease entity from HGSC, controversy remains as to whether the 
criteria used for NAC in non-HGSC should be the same as those 
for HGSC and whether the same chemotherapy regimen used 
for HGSC should be applied for non-HGSC.
We applied the same criteria and the same chemotherapy 
regimen for NAC regardless of histologic subtypes. The aim of 
this study was to evaluate the survival difference between pa-
tients with non-HGSC versus HGSC advanced ovarian cancer 
treated with NAC.
MATERIALS AND METHODS
We performed a retrospective analysis of medical records of 
843 patients diagnosed with epithelial ovarian cancer from 
January 2006 to September 2017 at Yonsei Cancer Hospital. 
The present study was approved by the Institutional Review 
Board (IRB) of Severance Hospital at Yonsei University College 
of Medicine (IRB no. 4-2018-0518).
The inclusion criteria were as follows: 1) histologically con-
firmed diagnosis of epithelial ovarian cancer, 2) International 
Federation of Gynecology and Obstetrics (FIGO) stage III or 
IV epithelial ovarian cancer, 3) treatment with at least one cy-
cle of NAC, and 4) availability of medical records and patholo-
gy slides. Fig. 1 shows a flow diagram of the study population. 
Of the 843 patients examined during the study period, we ex-
cluded 4 patients who refused treatment and 619 patients 
who underwent PDS. Of 220 patients who received more than 
one cycle of NAC, 10 patients with FIGO stage I or II and 23 
patients without available pathologic slides for review were 
excluded. The remaining 187 patients (HGSC, n=162; non-
HGSC, n=25) were included in this study.
All patients underwent CT and PET/CT as preoperative im-
aging workup. After patients were clinically diagnosed as hav-
ing FIGO stage III or IV, the pathologic diagnosis of epithelial 
ovarian cancer was made by cytologic evaluation of ascites/
pleural effusion, image-guided aspiration biopsy, and diagnos-
tic laparoscopic/laparotomy biopsy. Our institution applied 
the following selection criteria for the use of NAC as the pri-
mary treatment strategy regardless of histologic subtypes:18 
Fig. 1. Flow diagram of the study population. FIGO, International Federation 
of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; LGSC, 
low-grade serous carcinoma.
Epithelial ovarian cancer 
in 2006–2017
n=843
Neoadjuvant 
chemotherapy
n=220
HGSC
n=162
Non-HGSC (n=25)
   Clear cell (n=9), mucinous (n=4), endometrioid (n=4),
   LGSC (n=3), carcinosarcoma (n=3), squamous cell (n=1),
   undifferentiated (n=1)
Treatment exclusion criteria (n=623)
   No treatment       n=4
   Primary debulking surgery      n=619
Stage/histology exclusion criteria (n=33)
   FIGO stage I–II       n=10
   Not available slides      n=23
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and non-HGSC groups. Differences in categorized variables 
between patients with HGSC and non-HGSC were tested by 
Pearson’s chi-square test and Fisher’s exact test. For continu-
ous variables, Student’s t-test or Mann-Whitney’s U tests were 
used to compare groups. Kaplan-Meier survival curves were 
calculated and compared using the log-rank test. Univariate 
and multivariate analyses were assessed using a Cox propor-
tional hazard model to evaluate prognostic factors affecting 
PFS and OS. p values less than 0.05 were considered indica-
tive of statistical significance. All analyses were conducted us-
ing IBM SPSS, version 23 for Windows (IBM Corp., Armonk, 
NY, USA).
RESULTS
Table 1 summarizes the baseline characteristics of the study 
population. Median age and BMI at diagnosis, as well as ASA 
score, did not differ between the HGSC and non-HGSC groups. 
In contrast, the median baseline CA-125 level before chemo-
therapy was lower in the non-HGSC group than in the HGSC 
group (351.3 U/mL vs. 2005.5 U/mL, p<0.001). The number of 
patients with FIGO stage IV was significantly higher in the 
HGSC group than in the non-HGSC group (74.1% vs. 48.0%, 
p=0.008). There was no significant difference in the number of 
NAC/POAC cycles between the two groups. Despite not 
achieving statistical significance, there was a tendency toward 
a higher number patients with more than six cycles of total 
chemotherapy in the HGSC group, compared to the non-HG-
SC group (153 vs. 21, p=0.077).
The median follow-up duration was 24.1 months (range: 
0.1–106.3 months), during which there were 142 cases of re-
currence and 71 deaths. Table 2 shows the treatment out-
comes after NAC/IDS between the two histologic subtypes. 
The number of patients with more than a 90% reduction in 
CA-125 levels (comparing baseline and after the third NAC 
treatment) was greater in the HGSC group than in the non-
HGSC group (74.1% vs. 28.0%, p<0.001). A significantly higher 
response rate after the third NAC treatment was found in the 
HGSC group than in the non-HGSC group (87.7% vs. 56.0%, 
p<0.001). The numbers of patients who achieved optimal de-
bulking surgery (residual disease ≤1 cm) comprised 137 
(84.6%) patients in the HGSC group and 16 (64.0%) patients in 
the non-HGSC group (p=0.003). There were no significant dif-
ferences in the extent of surgery, lymphadenectomy, lymph 
node metastasis, and peritoneal cytology.
Of 25 patients with non-HGSC, histologic subtypes includ-
ed clear cell carcinoma (n=9, 36.0%), mucinous adenocarci-
noma (n=4, 16.0%), endometrioid adenocarcinoma (n=4, 
16.0%), LGSC (n=3, 12.0%), carcinosarcoma (n=3, 12.0%), 
squamous cell carcinoma (n=1, 4.0%), and undifferentiated 
carcinoma (n=1, 4.0%).
Various methods were used to diagnose ovarian cancer be-
fore NAC: 13 by diagnostic laparoscopy (52.0%), nine by cytol-
ogy of ascites (36.0%), two by pleural effusion cytology (8.0%), 
and one by aspiration biopsy (4.0%). After these diagnostic 
methods were performed, histologic subtypes could be deter-
mined in only eight cases (32.0%) before NAC. The reasons 
(multi-selectable) for NAC in patients with non-HGSC were 
high tumor burden (n=25, 100%), old age/poor Eastern Coop-
erative Oncology Group (n=2, 8.0%), diagnosis of HGSC be-
fore NAC (n=2, 8.0%), and being referred from another hospi-
tal after NAC (n=1, 4.0%) (Table 3).
The Kaplan-Meier curves and the log rank test results showed 
that patients with non-HGSC had significantly poorer PFS 
(median PFS 10.3 months vs. 18.3 months; p=0.009) and OS 
(median OS 25.5 months vs. 60.6 months; p<0.001) than those 
with HGSC (Fig. 2). Table 4 demonstrates the cumulative haz-
ards of adverse outcomes in patients receiving NAC. Multivar-
iate analyses indicated non-HGSC as a negative predictor for 
both PFS [hazard ratio (HR), 3.19; 95% confidence interval 
(CI), 1.73–5.88] and OS (HR, 4.22; 95% CI, 2.07–8.58) in pa-
Table 1. Baseline Characteristics of the Patients with HGSC and Non-
HGSC
Characteristics
NAC
p valueHGSC 
(n=162)
Non-HGSC 
(n=25)
Age (yr) 57 (27–80) 57 (31–66) 0.165
BMI at diagnosis (kg/m2)
23.1 
(17.6–35.2)
21.4
(16.4–28.8)
0.059
Baseline CA-125 level (U/mL)
2005.5 
(74.0–30000.0)
351.3 
(44.0–17303.0)
<0.001
FIGO stage 0.008
III 42 (25.9) 13 (52.0)
IV 120 (74.1) 12 (48.0)
ASA score 0.235
1–2 114 (70.4) 15 (60.0)
3–4 45 (27.8) 10 (40.0)
Unknown 3 (1.8) 0 (0.0)
Cycles of NAC 3 (1–6) 3 (2–9) 0.735
Number of NAC cycles
<4 125 (77.2) 16 (64.0) 0.155
≥4 37 (22.8) 9 (36.0)
Cycles of POAC 5 (0–9) 3 (0–7) 0.296
Number of POAC cycles 0.531
<4 67 (41.4) 12 (48.0)
≥4 95 (58.6) 13 (52.0)
Cycles of total chemotherapy 8 (1–12) 7 (5–12) 0.373
Number of total chemotherapy 0.077
<6 9 (5.6) 4 (16.0)
≥6 153 (94.4) 21 (84.0)
HGSC, high-grade serous carcinoma; BMI, body mass index; CA-125, cancer 
antigen 125; FIGO, International Federation of Gynecology and Obstetrics; 
ASA, American Society of Anesthesiologists; NAC, neoadjuvant chemothera-
py; POAC, postoperative adjuvant chemotherapy.
Data are presented as median (range) or number (%).
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tients who underwent NAC.
DISCUSSION
In this study, we found that patients with non-HGSC experi-
enced a poorer response rate, lower rate of optimal debulking 
surgery, and poorer PFS and OS than those with HGSC. Fur-
thermore, our results showed that the non-HGSC subtype is 
an independent prognostic factor for PFS and OS in patients 
with advanced ovarian cancer who undergo NAC.
Epithelial ovarian cancer includes a diverse group of hetero-
geneous neoplasms, with the five main subtypes being HGSC, 
endometrioid, clear cell, mucinous, and LGSC. In recent 
years, understanding of the underlying pathogenesis and the 
onset of molecular events in the different histologic subtypes 
has greatly increased, and although ovarian cancer is often clini-
cally considered a single disease, there is now recognition that 
the various subtypes have different features and prognoses.21 
Confirming the histological subtype of ovarian carcinoma be-
fore NAC is difficult. In most cases, the histologic subtypes 
cannot be confirmed by cytologic evaluation of ascites and 
pleural effusions; however, they can be determined from tissue 
obtained by performing diagnostic laparoscopy. In the EORTC 
55971 trial and CHORUS trial, if a biopsy was not possible, pa-
tients with a CA-125 to carcinoembryonic antigen ratio greater 
than 25 were enrolled in order to exclude primary gastrointes-
tinal tumors, and histologic subtype confirmation of diagnosis 
was not needed before randomization.16,17 In our study, diag-
nostic laparoscopy was performed as a diagnostic method in 13 
cases; however, NAC was administered according to criteria, 
Table 3. Characteristics of Patients with Non-HGSC
Characteristics n (%)
Histologic subtype
Mucinous 4 (16.0)
Endometrioid 4 (16.0)
Clear cell 9 (36.0)
LGSC 3 (12.0)
Carcinosarcoma 3 (12.0)
Squamous cell carcinoma 1 (4.0)
Unknown 1 (4.0)
Method of diagnosis
Ascites cytology 9 (36.0)
Pleural effusion cytology 2 (8.0)
Aspiration biopsy 1 (4.0)
Diagnostic laparoscopy 11 (44.0)
Diagnostic laparotomy 0 (0.0)
Laparoscopy in other hospital 2 (8.0)
Laparotomy in other hospital 0 (0.0)
Confirm the histologic subtypes before NAC
No 17 (68.0)
Yes 8 (32.0)
HGSC 2 (8.0)
Mucinous 2 (8.0)
Endometrioid 0 (0.0)
Clear cell 3 (12.0)
LGSC 1 (4.0)
Carcinosarcoma 0 (0.0)
Reasons for performing NAC
Old age/poor ECOG 2 (8.0)
High tumor burden 25 (100.0)
Considered as HGSC before NAC 2 (8.0)
Referred from another hospital after NAC 1 (4.0)
HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; NAC, 
neoadjuvant chemotherapy; ECOG, Eastern Cooperative Oncology Group.
Table 2. Treatment Outcomes after NAC/IDS for HGSC and Non-HGSC
Characteristics
NAC
p valueHGSC 
(n=162)
Non-HGSC 
(n=25)
NAC response
CA-125, n (%)
CA-125 reduction rate ≥90% 120 (74.1) 7 (28.0) <0.001
Response rate after 3rd NAC, n (%) <0.001
CR 1 (0.6) 1 (4.0)
PR 141 (87.1) 13 (52.0)
SD 13 (8.0) 7 (28.0)
PD 1 (0.6) 3 (12.0)
Unknown 6 (3.7) 1 (4.0)
Surgical outcome
Surgery extent, n (%) 0.848
Standard 90 (55.6) 13 (52.0)
Radical 70 (43.2) 11 (44.0)
Not surgery 2 (1.2) 1 (4.0)
Residual disease after IDS, n (%) 0.003
≤1 cm 137 (84.6) 16 (64.0)
>1 cm 7 (4.3) 6 (24.0)
Unknown 18 (11.1) 3 (12.0)
Lymphadenectomy, n (%) 0.324
(–) 13 (8.0) 3 (12.0)
(+) 147 (90.7) 20 (80.0)
Unknown 2 (1.3) 2 (8.0)
Lymph node metastasis, n (%) 0.717
No 91 (56.2) 14 (56.0)
Yes 69 (42.6) 9 (36.0)
Unknown 2 (1.2) 2 (8.0)
Peritoneal cytology, n (%) 0.573
Negative 28 (17.3) 5 (20.0)
Positive 62 (38.3) 6 (24.0)
Not tested 68 (42.0) 13 (8.0)
Unknown 4 (2.4) 1 (4.0)
NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; HGSC, 
high-grade serous carcinoma; CA-125, cancer antigen 125; CR, complete re-
sponse; PR, partial response; SD, stable disease; PD, progressive disease.
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Fig. 2. Kaplan-Meier survival curves of (A) PFS and (B) OS according to histological subtype. HGSC, high-grade serous carcinoma; PFS, progression-free sur-
vival;  OS, overall survival. 
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Table 4. Univariate and Multivariate Analyses for Progression-Free and Overall Survival Using the Cox Proportional Hazards Model
Variables
PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI)    p value HR (95% CI)    p value HR (95% CI)    p value HR (95% CI)    p value
Age (yr)
<60 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
≥60 0.97 (0.70–1.36)   0.875 1.24 (0.82–1.88)   0.313 1.61 (1.01–2.57)   0.045 2.47 (1.39–4.39)   0.002
ASA
1–2 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
3–4 1.06 (0.73–1.54)   0.761 0.91 (0.57–1.44)   0.677 1.47 (0.83–2.60)   0.185 1.20 (0.58–2.46)   0.627
Baseline CA-125 level (U/mL)
≤1000 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
>1000 1.01 (0.70–1.44)   0.972 1.17 (0.78–1.77)   0.445 0.86 (0.52–1.41)   0.540 1.21 (0.64–2.27)   0.555
FIGO stage  
III 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
IV 1.36 (0.93–2.00)   0.114 1.65 (1.03–2.66)   0.038 0.53 (0.33–0.87)   0.011 0.59 (0.31–1.13)   0.112
Histology
HGSC 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Non-HGSC 1.20 (1.17–3.26)   0.010 3.19 (1.73–5.88)   <0.001 3.28 (1.81–6.07)   <0.001 4.22 (2.07–8.58)   <0.001
Residual disease
NGR 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
>0 1.65 (1.14–2.39)   0.008 1.64 (1.12–2.40)   0.012 1.89 (1.05–3.42)   0.034 1.89 (0.99–3.60)   0.051
Surgery extent
Standard 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Radical 1.16 (0.83–1.62)   0.374 0.87 (0.59–1.27)   0.471 0.98 (0.60–1.60)   0.946 0.98 (0.54–1.78)   0.939
LND
No 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Yes 0.71 (0.41–1.23)   0.225 0.54 (0.27–1.11)   0.094 0.56 (0.27–1.18)   0.129 0.45 (0.15–1.37)   0.162
LN meta
No 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Yes 1.58 (1.13–2.21)   0.007 1.83 (1.26–2.66)   0.001 1.33 (0.82–2.14)   0.252 2.51 (1.40–4.50)   0.002
Number of total chemotherapy cycles
<6 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
≥6 0.81 (0.33–1.99)   0.646 0.41 (0.16–1.04)   0.060 0.22 (0.11–0.44)   <0.001 0.21 (0.08–0.51)   0.001
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; CA-125, cancer antigen 125; 
FIGO, International Federation of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; NGR, no gross residual disease; LND, lymph node dissection; LN, 
lymph node.
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such as high tumor burden, regardless of histologic subtype.
Several studies have evaluated the prognosis of patients 
with non-HGSC who have undergone PDS. Hosono, et al.6 re-
ported that suboptimal residual tumor size was associated 
with poorer prognosis in non-serous subtype tumors, but not 
in serous subtype tumors. Melamed, et al.7 reported that there 
is no prognostic significance of residual disease status by his-
tologic subtype. Mackay, et al.8 showed that mucinous and clear 
cell carcinomas are poor prognostic factors in stage III/IV ovar-
ian cancer. Simons, et al.10 also suggested that patients with 
mucinous ovarian carcinoma have a significantly worse prog-
nosis than patients with advanced-stage serous ovarian carci-
noma.
NAC followed by IDS has been widely used for advanced-
stage ovarian cancer, particularly for patients with an unre-
sectable high tumor burden, old age, and a poor performance 
status. However, characteristics of the response patterns and 
survival outcomes of patients with non-HGSC who received 
NAC have not yet been published. In the NAC setting, the ef-
fect of debulking surgery is excluded, and chemo-sensitivity 
during NAC is a well-known prognostic factor for survival. 
Therefore, we could predict that patients with non-HGSC may 
have a poor prognosis due to resistance and may be less sen-
sitive to taxane-platinum chemotherapy.
Recent advances in pathology and genetics have provided 
insights into the pathophysiologic features and natural history 
of ovarian cancer. For example, several studies have demon-
strated that LGSC, mucinous, endometrioid, and clear cell car-
cinomas are characterized by mutations involving KRAS/BRAF, 
KRAS, CTNNB1, and PIK3CA genes, respectively.22-24 There-
fore, a tailored approach should be considered for this hetero-
geneous disease.
Many studies have evaluated histologic subtype-specific 
treatment of ovarian cancer. In the JGOG 3017 study, the al-
ternative chemotherapy agent irinotecan combined with cis-
platin was compared to conventional paclitaxel plus carbopl-
atin for clear cell carcinoma in a randomized, phase III trial, 
with no significant survival benefit observed in the irinotecan 
plus cisplatin arm.12 Furthermore, there are currently two on-
going histology subtype-specific studies: one evaluating mito-
gen-activated protein kinase inhibitors in LGSC subtype tu-
mors and one evaluating carboplatin and paclitaxel versus 
oxaliplatin and capecitabine with or without bevacizumab in 
mucinous subtype tumors. The Gynecologic Oncology Group 
recently completed accrual of a front-line, phase II trial of 
temsirolimus (mammalian target of rapamycin inhibitor) plus 
paclitaxel/carboplatin as first-line therapy for treating patients 
with newly diagnosed stage III/IV clear cell carcinoma. How-
ever, clinical data specific to subtypes are limited; thus, there 
is an unmet need for novel treatments according to histologic 
subtypes of ovarian carcinoma.22-24
Several potential limitations of this study should be consid-
ered. First, the selection bias resulting from its retrospective 
nature may affect the results. Second, due to the increased use 
of NAC in recent years, this study is limited by the short fol-
low-up period. Further studies with long-term follow-up are 
required for accurate evaluation of survival outcomes. Third, 
the non-HGSC group included several histologic subtypes 
because of the small patient sample. However, each subtype is 
considered to have distinctive morphologic and molecular 
genetic features that could affect study outcomes. Therefore, 
future studies with larger numbers of patients are needed to 
evaluate the subtype-specific outcomes among patients with 
NAC.
Despite these limitations, our study has the following 
strengths. Since we applied the same criteria and the same 
chemotherapy regimen for NAC regardless of histologic sub-
types during the study period, the comparison of non-HGSC 
and HGSC might be justified.
In conclusion, histologic subtype is an independent prog-
nostic factor for patients undergoing NAC for advanced-stage 
ovarian carcinoma, and patients with non-HGSC showed 
poorer survival than those with HGSC. Therefore, different se-
lection criteria and different treatment strategies for NAC 
should be applied to patients with non-HGSC.
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